In last trading session, Avidity Biosciences Inc (NASDAQ:RNA) saw 3.15 million shares changing hands with its beta currently measuring 1.02. Company’s recent per share price level of $29.77 trading at $3.03 or 11.33% at ring of the bell on the day assigns it a market valuation of $3.58B. That closing price of RNA’s stock is at a discount of -88.11% from its 52-week high price of $56.00 and is indicating a premium of 27.58% from its 52-week low price of $21.56. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.86 million shares which gives us an average trading volume of 1.40 million if we extend that period to 3-months.
For Avidity Biosciences Inc (RNA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.07. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.88 in the current quarter.
Avidity Biosciences Inc (NASDAQ:RNA) trade information
Upright in the green during last session for gaining 11.33%, in the last five days RNA remained trading in the red while hitting it’s week-highest on Thursday, 03/27/25 when the stock touched $29.77 price level, adding 10.14% to its value on the day. Avidity Biosciences Inc’s shares saw a change of 2.37% in year-to-date performance and have moved -7.11% in past 5-day. Avidity Biosciences Inc (NASDAQ:RNA) showed a performance of 4.24% in past 30-days. Number of shares sold short was 16.13 million shares which calculate 12.47 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 54.5 to the stock, which implies a rise of 45.38% to its current value. Analysts have been projecting 50 as a low price target for the stock while placing it at a high target of 59. It follows that stock’s current price would drop -67.95% in reaching the projected high whereas dropping to the targeted low would mean a loss of -67.95% for stock’s current value.
Avidity Biosciences Inc (RNA) estimates and forecasts
This year revenue growth is estimated to fall -23.41% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.62M for the same. And 8 analysts are in estimates of company making revenue of 2.51M in the next quarter. Company posted 3.54M and 2.04M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -34.37% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -32.24% while estimates for its earnings growth in next 5 years are of 0.06%.
Avidity Biosciences Inc (NASDAQ:RNA)’s Major holders
Insiders are in possession of 5.03% of company’s total shares while institution are holding 107.34 percent of that, with stock having share float percentage of 113.02%. Investors also watch the number of corporate investors in a company very closely, which is 107.34% institutions for Avidity Biosciences Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at RNA for having 16.16 million shares of worth $660.1 million. And as of 2024-06-30, it was holding 15.1121 of the company’s outstanding shares.
The second largest institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, which was holding about 10.92 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.5173 of outstanding shares, having a total worth of $445.94 million.
On the other hand, T. Rowe Price New Horizons Fund, Inc. and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 4.43 shares of worth $131.82 million or 3.68% of the total outstanding shares. The later fund manager was in possession of 3.5 shares on Dec 31, 2024 , making its stake of worth around $104.25 million in the company or a holder of 2.91% of company’s stock.
